Xpention Genetics, Inc. Extends Research Agreement With The University of Texas Health Science Center At San Antonio
Published: Feb 20, 2007
CONIFER, CO -- (MARKET WIRE) -- February 20, 2007 -- Xpention Genetics, Inc. (OTCBB: XPNG) has extended the Research Agreement with The University of Texas Health Science Center at San Antonio (UTHSCSA) through May 31, 2007. The extension will permit completion of the research activities for the project entitled "Development of the p65 Immunological Test" as well as permit the continued collaboration with Dr. Margaret Hanausek, one of the co-inventors of the p65 technology. As part of the extension, Dr. Hanausek will be able to work on additional research projects involving further development of the p65 technology for both canines and humans. P65 is a promising marker for the early detection of malignant tumor formation and a useful tool for monitoring therapy and remission. Levels of p65 also appear to have a direct correlation to tumor size. The cancer test under development will use p65 technology licensed by Xpention, Inc., a wholly owned subsidiary of the Company, from The University of Texas MD Anderson Cancer Center.